Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients

Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation

(2021) Sandeep Kumar Parvathareddy et al.   Scientific Reports

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

(2021) Yu Rebecca Miao et al.   CLINICAL CANCER RESEARCH

The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer

(2020) Marek Nowak et al.   Cells

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

(2020) V. Gambardella et al.   CANCER TREATMENT REVIEWS

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

(2020) Karolina Okła et al.   Journal of Translational Medicine

Dendritic cell therapy in cancer treatment; the state-of-the-art

(2020) Mahsa Sadeghzadeh et al.   LIFE SCIENCES

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas

(2020) Kunihiro Asanuma et al.   Scientific Reports

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis

(2020) Hidetaka Yasuoka et al.   Scientific Reports

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

(2020) Qi Peng et al.   Nature Communications

Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer

(2020) Iwona Wertel et al.   Journal of Immunology Research

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients

(2020) Anna Pawłowska et al.   Cancer Management and Research

Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review)

(2019) Guyu Zhang et al.   Oncology Letters

Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

(2019) Huayu Yang et al.   Frontiers in Oncology

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer

(2019) Chunyan Xue et al.   Translational Cancer Research

The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication

(2019) Rosalba De Nola et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells

(2019) Claudia Carenza et al.   Frontiers in Immunology

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

(2019) Yiyin Zhang et al.   Journal for ImmunoTherapy of Cancer

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer

(2019) Paul Buderath et al.   Frontiers in Oncology

The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies

(2019) Oliviero Marinelli et al.   Frontiers in Oncology

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker

(2018) Juan Fernando Sánchez Vega et al.   BMC CANCER

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design

(2018) Eric Pujade-Lauraine et al.   Future Oncology

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors

(2018) Wei Wei et al.   MEDICINE

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment

(2018) Tyvette Hilliard   Cancers

Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment

(2018) Maureen L. Drakes et al.   Cancers

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer

(2018) SHINKICHI TAKAMORI et al.   ANTICANCER RESEARCH

Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment

(2018) A. Pawłowska et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients

(2018) Karolina Okła et al.   TUMOR BIOLOGY

Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors

(2017) Chelsea E. Gottlieb et al.   GYNECOLOGIC ONCOLOGY

Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

(2017) Xinxin Zhu et al.   Journal of Gynecologic Oncology

The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma

(2017) Kazuki Takada et al.   LUNG CANCER

The effect of CA125 on metastasis of ovarian cancer: old marker new function

(2017) Qin Yuan et al.   Oncotarget

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

(2017) Stefanie Aust et al.   Scientific Reports

The Dualistic Model of Ovarian Carcinogenesis

(2016) Robert J. Kurman et al.   AMERICAN JOURNAL OF PATHOLOGY

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications

(2016) Ivo Meinhold-Heerlein et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer

(2016) Jayanta Chatterjee et al.   CLINICAL CANCER RESEARCH

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

(2016) Lucia Festino et al.   DRUGS

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

(2016) John R. Webb et al.   GYNECOLOGIC ONCOLOGY

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

The prognostic significance of PD-L1 in bladder cancer

(2015) YIDE HUANG et al.   ONCOLOGY REPORTS

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

(2015) Silvia Darb-Esfahani et al.   Oncotarget

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics

(2015) Jie Zhang et al.   Thoracic Cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity

(2013) Osama A.O. Elhag et al.   Asian Pacific Journal of Cancer Prevention

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

(2013) Christian J. Maine et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Staging classification for cancer of the ovary, fallopian tube, and peritoneum

(2013) Jaime Prat et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection

(2013) D O'Shea et al.   INTERNATIONAL JOURNAL OF OBESITY

B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells

(2013) Sheng-Jia Shi et al.   PLoS One

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Soluble B7-H1: Differences in production between dendritic cells and T cells

(2011) Xavier Frigola et al.   IMMUNOLOGY LETTERS

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer

(2008) I. Wertel et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY